Zhejiang Medicine Co Ltd DMF, CEP, Written Confirmations, FDF, Prices, Patents, Patents & Exclusivities, Dossier, Manufacturer, Licensing, Distributer, Suppliers, News, GMP

Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

Virtual Booth

Contact Supplier

Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

VISIT THE VIRTUAL BOOTH
Review portfolio & marketing content
CONTACT DETAILS
Google Map, LinkedIn, Emails...

DIGITAL CONTENT

5 News #PharmaBuzz

media
5 News #PharmaBuzz

ACTIVE PHARMA INGREDIENTS

171 All APIs, 12 USDMF, 15 CEP/COS, 6 JDMF, 155 KDMF, 9 NDC API, 13 Listed APIs

171 All APIs
12 USDMF
15 CEP/COS
6 JDMF
155 KDMF
9 NDC API
13 Listed APIs

DEVELOPMENTS

6 Drugs in Development

6 Drugs in Development

FINISHED DOSAGE FORMULATIONS

7 FDF Dossiers, 7 FDA Orange Book

7 FDF Dossiers
7 FDA Orange Book

REF. STANDARDS & IMPURITIES

1 Others

otherProducts
1 Others

INSPECTIONS & REGISTRATIONS

4 FDA, 1 EDQM, 1 GDUFA, 3 Third-Party Audit

inspections
4 FDA
1 EDQM
1 GDUFA
3 Third-Party Audit

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Zhejiang Medicine Co., Ltd. is a large-scale joint-stock comprehensive pharmaceutical enterprise which was set up in May 1997. Being approved in August 1999 by the China Securities Regulatory Commission, the company issued 58 million A shares to the public, and in October of the same year the company shares were listed on the Shanghai Securities Exchange. Up to the third quarter of 2013, the registered capital has reached CNY 930,000,000, and the total assets have reached CNY 7,300,000,000. Zhejiang Medicine Co. Ltd. owns five subsidiaries including Xinchang Pharmaceutical Factory, Vitamin Factory, Zhejiang Changhai Biological Co. Ltd., Zhejiang Health Creation Bio-technology Co. Ltd., and Zhejiang Health Creation Pharmaceutical Co. Ltd., and two R&D units including Research Institute of Pharmaceutical Industry and Shanghai Health Creation Bio-Pharmaceutical R&D Center. The company has been rated as "National High-tech Enterprise" and "National Innovative Enterprise", which owns state-level enterprise technology center and also has established a postdoctoral research station. There are more than 5000 employees, more than 2000 of which are professional technicians accounting for more than 40%. At present, Zhejiang Medicine Co. Ltd. is specialized in the large-scale production of fat-soluble vitamins, quasi-vitamins, quinolone antibiotics, anti-drug-resistant antibiotics and other products. Its output of vitamin E is the largest domestically, and the 2nd largest globally; the output of Vancomycin hydrochloride accounts for more than 40% of the global production; it is the largest vendor of β-carotene and canthaxanthin domestically, and the 3rd globally; the output of Coenzyme Q10 accounts for 20% of the global production. Through earnestly implementing the development strategy of " innovation, competition, science and technology as well as talent thriving are all critical in the development of the company", Zhejiang Medicine Co., Ltd. tightly holds the main line of product development, highlights the structure adjustment and integration of various resources, strengthens the original technological innovation and competitive product technology innovation, does well on DMF file registration and FDA certification for some competitive varieties, actively promotes clean production and circular economy, builds perfect market network by taking globalization as standpoint, establishes good brand image , building up advanced enterprise culture, and strongly promotes the core competitiveness. Currently, Zhejiang Medicine Co., Ltd. has become a large-scale pharmaceutical company with advanced technology, strong capital and technical strength which has an influence in the global market.